1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

INITIATOR PHARMA: Q1 2026 REPORT

MARKN.

Business highlights in Q1 2026

  • In February the Company announced that the European Patent Office (EPO) has granted the Company’s European patent application covering pudafensine for the treatment of Female Sexual Dysfunction (FSD)

Business highlights after this reporting period

  • In April the Company announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the Company will discontinue further development of IP2018
  • In April the Company announced good progress in patient enrolment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia

Financial Highlights

First Quarter (2026-01-01 – 2026-03-31)
Net revenue were KDKK 0 (0)
Operating loss, EBIT was KDKK -11,432 (-2,653)
Earnings per share before and after dilution was DKK -0.17 (-0.05)
Cash: KDKK 19,803 (26,245)
Solidity: 68% (88%)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

INIT 2026 Q1 Final

Datum 2026-05-08, kl 08:30
Källa MFN
Bifogade filer
INIT 2026 Q1 Final